APA (7th ed.) Citation

Simsek, B., Niman, S., El Ahmar, N., Mohanna, R., Delcea, A., De Oliveira, G., . . . Signoretti, S. (2025). 2613MO Identifying biomarkers of response to first-line nivolumab plus ipilimumab therapy in patients with metastatic clear cell renal cell carcinoma (mccRCC) enrolled in the COSMIC 313 trial. Annals of Oncology, 36, S1402. https://doi.org/10.1016/j.annonc.2025.08.3228

Chicago Style (17th ed.) Citation

Simsek, B., et al. "2613MO Identifying Biomarkers of Response to First-line Nivolumab Plus Ipilimumab Therapy in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Enrolled in the COSMIC 313 Trial." Annals of Oncology 36 (2025): S1402. https://doi.org/10.1016/j.annonc.2025.08.3228.

MLA (9th ed.) Citation

Simsek, B., et al. "2613MO Identifying Biomarkers of Response to First-line Nivolumab Plus Ipilimumab Therapy in Patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) Enrolled in the COSMIC 313 Trial." Annals of Oncology, vol. 36, 2025, p. S1402, https://doi.org/10.1016/j.annonc.2025.08.3228.